Sling Therapeutics, Inc., a US-based biopharmaceutical company, announced on Monday that it has named Faheem Hasnain as its new chairman of the company's board of directors.
Hasnain has served as the founder, chief executive officer, and chairman of Gossamer Bio. He also holds the position of the lead independent director for Kura Oncology and is chairman of the board of directors for Aspen Neuroscience, Mirati Therapeutics and SENTÉ. He is the former president and chief executive officer of Receptos, Facet Biotech and PDL BioPharma.
Hasnain has a BHK and a BEd from the University of Windsor.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates